The current competitive landscape:

Knowledge and technology are the most important resources in modern innovation-based economies, in which big thoughts and new networks are essential. The Nanomedicine & Nanodrugs ZPH GmbH enterprise would be an excellent opportunity to expand the knowledge of advanced nanoscience, new market’s penetration, new product development, market expansion and diversification in the nanomedicine business.

There are no direct or indirect competition in the market or in the pipeline, or among clinical trials or patent database, for ZPH nanodrugs and nanoformulations, because the optical and electronic (optoelectronic) properties in quantum size regime could be tailored widely, simply as a function of size, shape, and surface chemistry. This will greatly impact the efficacy of the treatments and off-target side-effects.

Business model and growth strategy:

Towards the next generation of great discoveries, major drug developers could rely more heavily on partnerships with small, innovative, and entrepreneur-led companies instead on large, monolithic organizations.

The turnover of ZPH nanodrug.
—————————–
If we consider just anti-breast cancer nanodrug, and not other products and other activities.
If we consider just 2 countries out of 195 countries. = Germany and USA.
The turnover potential for the market plus the Ebit (as profitability measures) of ZPH nanodrug has beed calculated in the business plan .

It is possible!

Today, there exist examples of incubation, illumination, and verification of nano-drugs with high potential rewards “in the commercialization of nanotechnology”. Therewith, the costs of essential R&D process, tricky access to funds, uncertainty of expected returns, and the meticulous FDA regulatory process have not deterred the investors’ community and the effects of Life-giving researches.

As our company’s expertise and special knowledge are very unique, the amplification of the ZPH image and brand identity will happen quickly and globally.